This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Despite proven benefits in reducing morbidity and mortality, many heartfailure (HF) patients do not receive optimal guideline-directed medical therapy (GDMT). The 2021 European Society of Cardiology guidelines recommend guideline-directed medical therapy (GDMT) for patients with HF with reduced ejection fraction (HFrEF).
RELIEVE-HF investigators evaluated the efficacy and safety of the V-wave interatrial shunt system in patients with heartfailure. The primary endpoint was a composite of all-cause mortality, left ventricular assist device (LVAD)/heart transplantation, HF hospitalizations, worsening HF, and KCCQ score changes. April 6, 2024.
Current Role of Digoxin in HeartFailure as Per Guidelines and DIGIT-HF trial of Digitoxin Use of digoxin in heartfailure has come down markedly over the past decades due to concerns of toxicity and availability of more effective medications. Eur Heart J. Erratum in: Eur Heart J. Eur J Heart Fail.
Outcomes: Over a median follow-up of 12.5 15.3), 3.3% (n = 18) of patients died, with heartfailure events most common in RCM patients (36.0%). Differential outcomes across subtypes emphasize the need for personalized care pathways, informing targeted interventions to optimize prognosis in pediatric cardiomyopathy patients.
In a recent study published in Circulation: HeartFailure , researchers analyzed a large group of individuals with various cardiopulmonary diseases who had undergone right heart catheterization. year follow-up, those with right ventricular dysfunction faced an increased risk of mortality and heartfailure hospitalization.
The Sleep Heart Health Study found that obstructive sleep apnea with excessive daytime sleepiness triples the chance of heartfailure and doubles the risk of a heart disease event. The same subtype was associated with increased risk of new occurrence of heart disease. Wait before taking it so lightly.
Mark Schuuring discuss the results of the ADMINISTER2 trial ( NCT05413447 ) which investigated whether the use of digital consults (DCs) could enhance the adoption of guideline-directed medical therapy (GDMT) in patients with heartfailure and reduced ejection fraction (HFrEF).
That is due to impaired flow through the coronary microcirculation and is associated with higher mortality as well as chance for left ventricular dysunction and heartfailure. In the initial era of primary PCI, angiographic myocardial blush was taken as a surrogate of effective myocardial reperfusion.
AF-CHF trial in those with AF and congestive heartfailure also failed to show any advantage for the rhythm control strategy [3]. Overall, it appears that rhythm control strategy in AF may be better in those with heartfailure and in those with associated cardiovascular conditions and early AF.
This multicenter open-label, blinded-outcome, randomized trial ( NCT04030234 ), offers new insights into hypertension management. The primary outcome measured was a composite of myocardial infarction, revascularisation, hospitalisation for heartfailure, stroke, or cardiovascular death, assessed over a median follow-up of 3.4
Investigators assessed if empagliflozin could lower the risk of hospitalization for heartfailure (HF) or death from cardiovascular disease (CVD). The percent change from baseline in fasting triglycerides (TG) at six months served as the primary outcome measure.
While the trial showed similar risk of cardiac events between INV and CON strategies, outcomes based on participant sex were not initially reported. As a result, this study aimed to fill this gap by analyzing ISCHEMIA outcomes according to participant sex. Original article: Gaudino M et al. EuroIntervention.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content